Traws Delays Influenza Study After UK Regulatory Setback
NEWTOWN, PA — Traws Pharma Inc. (NASDAQ: TRAW) has deferred a planned Phase 2a human influenza challenge study of its lead antiviral candidate tivoxavir marboxil after receiving unfavorable feedback from …
Traws Delays Influenza Study After UK Regulatory Setback Read More